Kiniksa Pharmaceuticals International Plc’s recent filing unveils that its CHIEF FINANCIAL OFFICER Ragosa Mark unloaded Company’s shares for reported $0.37 million on Mar 20 ’25. In the deal valued at $23.11 per share,15,944 shares were sold. As a result of this transaction, Ragosa Mark now holds 23,382 shares worth roughly $0.46 million.
Then, Ragosa Mark sold 11,464 shares, generating $264,818 in total proceeds. Upon selling the shares at $23.10, the CHIEF FINANCIAL OFFICER now owns 23,382 shares.
Before that, Ragosa Mark sold 8,879 shares. Kiniksa Pharmaceuticals International Plc shares valued at $205,105 were divested by the CHIEF FINANCIAL OFFICER at a price of $23.10 per share. As a result of the transaction, Ragosa Mark now holds 23,382 shares, worth roughly $0.46 million.
Citigroup initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on March 13, 2025; the price target was $40. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid September with a ‘”a Buy”‘ rating. Wells Fargo began covering KNSA with “an Overweight” recommendation on May 03, 2024. BofA Securities maintained its rating on June 29, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock fall -3.94% to $19.48. Over the last five days, the stock has lost -10.52%. Kiniksa Pharmaceuticals International Plc shares have fallen nearly -1.52% since the year began. Nevertheless, the stocks have risen 8.83% over the past one year. While a 52-week high of $28.15 was reached on 03/20/25, a 52-week low of $16.56 was recorded on 01/13/25. SMA at 50 days reached $20.98, while 200 days put it at $22.46.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 18.76, which if violated will result in even more drops to 18.03. On the upside, there is a resistance level at 20.76. A further resistance level may holdings at 22.03. The Relative Strength Index (RSI) on the 14-day chart is 32.13, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.45%. Stochastics %K at 12.31% indicates the stock is a buying.
How much short interest is there in Kiniksa Pharmaceuticals International Plc?
A steep rise in short interest was recorded in Kiniksa Pharmaceuticals International Plc stocks on 2025-03-14, growing by 0.11 million shares to a total of 3.07 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 2.96 million shares. There was a rise of 3.62%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 01, 2020 when BofA/Merrill began covering the stock and recommended ‘”a Buy”‘ rating along with a $25 price target.
